Long-term Effects of Imiquimod and Diclofenac in Actinic Keratoses (LEIDA)

• ClinicalTrials.gov Identifier: NCT00777127
• Recruitment Status: Completed
• First Posted: October 22, 2008
• Last Update Posted: February 1, 2013
• Sponsor: MEDA Pharma GmbH & Co. KG
• Information provided by (Responsible Party): MEDA Pharma GmbH & Co. KG

Tracking Information

• First Submitted Date: October 21, 2008
• First Posted Date: October 22, 2008
• Last Update Posted Date: February 1, 2013
• Study Start Date: December 2008
• Actual Primary Completion Date: November 2012 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: January 5, 2011)

Recurrence with respect to the study treatment area until month 12 [ Time Frame: week 20 until month 12 ]

A patient is classified as recurrent when cleared at Visit Week 20 and having later on at least one clinically diagnosed AK lesion in the study treatment area

• Original Primary Outcome Measures (submitted: October 21, 2008): a) Primary Endpoint: Recurrence with respect to the study treatment area. A patient is classified as recurrent when cleared at Visit Week 20 and having later on at least one clinically diagnosed AK lesion in the study treatment area. [ Time Frame: Week 20 ]

Current Secondary Outcome Measures (submitted: October 21, 2008)

• Time to recurrence [ Time Frame: 3 years ]
• Long-term outcome with respect to development of SCC (in situ and/or invasive) [ Time Frame: 3 years ]
• Need of rescue treatment [ Time Frame: 3 years ]
• Haematological changes [ Time Frame: 20 weeks ]
• Cosmetic outcome. [ Time Frame: 3 years ]

• Original Secondary Outcome Measures: Same as current
• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: Long-term Effects of Imiquimod and Diclofenac in Actinic Keratoses
• Official Title: Long-term Effects of Aldara® 5% Cream and Solaraze® 3% Gel in the Treatment of Actinic Keratoses on the Face or Scalp (LEIDA)
• Brief Summary: This clinical trial serves the purpose to compare the long-term effects of a treatment of actinic keratosis - your skin disorder - using Aldara® 5% cream or Solaraze® 3% gel on the face or the scalp. In particular, it should be found out whether the healing effect of these two medications on the skin lesions (i.e. the damaged skin parts) can be maintained for a prolonged period.
• Detailed Description: Not Provided
• Study Type: Interventional
• Study Phase: Phase 4
• Study Design: Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: None (Open Label); Primary Purpose: Treatment
• Condition: Actinic Keratosis

Intervention

• Drug: Imiquimod
  One course of treatment (COT) consisting of an overnight application of IMIQ (1 sachet for up to 50 cm2), applied 3 nights per week (e.g. Monday, Wednesday, Friday) for 4 weeks followed by a 4 weeks treatment pause. If necessary, this may be followed by a second COT.
• Drug: Diclofenac
  Solaraze® is applied locally to the skin 2 times daily and smoothed into the skin gently. The amount needed depends on the size of the lesion. Normally 0.5 grams (the size of a pea) of the gel is used on a 25 cm2 lesion site. The duration of therapy is 12 weeks.

Study Arms

• Experimental: 1
  Aldara 5% Cream
  Intervention: Drug: Imiquimod
• Active Comparator: 2
  Solaraze 3% Gel
  Intervention: Drug: Diclofenac

• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Completed
• Actual Enrollment (submitted: December 1, 2009): 258
• Original Estimated Enrollment (submitted: October 21, 2008): 240
• Actual Study Completion Date: November 2012
• Actual Primary Completion Date: November 2012 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

• Immunocompetent patient.
• A study treatment area must be identifiable: Minimum of 5 and maximum of 10 typical visible AKs in one contiguous area of up to 50 cm2 on the face or scalp. The eyelids, the inside of the nostrils or ears, or the lip area inside the vermilion border must not be part of this area.
• A positive histological finding for AK grade I or II (see Section 7.1.1.2). This will be determined from the most suspicious lesion in the STA and there from the most pathological area biopsied during screening visit. This analysis will be done by the central histopathological laboratory.
• Willingness to comply with the obligations of the study.

Exclusion Criteria:

Safety concerns:

• History of allergic reaction to imiquimod, diclofenac, acetyl salicylic acid, other non steroidal anti-inflammatory drugs (NSAID), hyaluronic acid, or relevant excipients.
• Pregnancy, breast-feeding or planned pregnancy during the study. Women of child bearing potential not using a highly effective method of birth control defined as those which result in a low failure rate (i.e. <1% per year) when used consistently and correctly such as implants, injectables, combined oral contraceptives, hormonal IUDs, tubal ligation or vasectomised partner.

Lack of suitability for the study:

• Presence of AK lesions in the STA with clinically marked hyperkeratosis or hypertrophy as seen in cutaneous horns.
• Any topical AK treatment including imiquimod or diclofenac, or any systemic AK treatment such as systemic retinoids, or any surgical AK treatment at the STA within the last 2 months prior to randomisation.
• Persisting AK lesion at screening visit following topical treatment with imiquimod or diclofenac in the STA.
• Topical treatment with imiquimod or diclofenac anywhere else on the body within the last 2 months prior to randomisation.
• Presence of any histologically confirmed skin tumour in the STA: in situ SCC including Bowen's disease, invasive SCC, basal cell carcinoma, or other malignant tumours.
• Any dermatological disease or condition that may exacerbate by treatment with imiquimod or diclofenac (e.g. rosacea, psoriasis, atopic dermatitis).
• Any dermatological disease or condition in the STA that causes difficulty with examination (e.g. eczema).
• Systemic immunomodulatory treatment such as interferon, azathioprine, cyclosporine, retinoids, any oral or injectable corticosteroids, or inhaled or nasal corticosteroids with dosages of >1200 µg/day beclomethasone or equivalent within 4 weeks before start of study treatment.
• History of any malignant tumour with high tumour burden or any systemic antitumour treatment (incl. radiotherapy).
• History of any malignant skin tumour having metastasised or where metastasis could be expected.
• History of severe cardiovascular, pulmonary, hepatic, renal, gastrointestinal, haematological, endocrine, metabolic, mental, neurological, or other disease within the last two years.
• Mentally incapacitated patient.
• Present or history of drug or alcohol abuse within the last 3 years.

Administrative reasons:

• Exposure to an investigational product within the last 3 months.
• Lack of ability or willingness to give informed consent.
• Age below 18 years.
• Lack of willingness to have personal study related data collected, archived or transmitted according to protocol.
• Anticipated non-availability for study visits/procedures.
• Vulnerable subjects (such as persons kept in detention).

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 18 Years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: Austria, France, Germany

Administrative Information

• NCT Number: NCT00777127
• Other Study ID Numbers: X-03016-3271; 2007-004884-24 ( EudraCT Number )
• Has Data Monitoring Committee: No
• U.S. FDA-regulated Product: Not Provided
• IPD Sharing Statement: Not Provided
• Responsible Party: MEDA Pharma GmbH & Co. KG
• Study Sponsor: MEDA Pharma GmbH & Co. KG
• Collaborators: Not Provided

Investigators

• Principal Investigator: Harald Gollnick, MD, Prof.; Otto-von-Guericke-University of Magdeburg/Germany, Clinic for Dermatology and Venereology
• Study Director: Ursula Petzold, PhD; MEDA Pharma GmbH & Co. KG, Bad Homburg/Germany

• PRS Account: MEDA Pharma GmbH & Co. KG
• Verification Date: January 2013